AWM
FOLD

Able Wealth Management’s Amicus Therapeutics FOLD Stock Holding History

Able Wealth Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-117
Closed -$1.66K – 259
2023
Q4 		$1.66K Buy
+117
New +$1.33K ﹤0.01% 478

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Able Wealth Management's FOLD Position: Q1 2024 in Review

Able Wealth Management sold out of Amicus Therapeutics (FOLD) in Q1 2024, closing a stake of 117 shares — an estimated $1.66K sold.

Able Wealth Management first reported a position in FOLD in Q4 2023 and held it in 1 quarter. The position peaked at $1.66K in Q4 2023. 254 funds tracked by Wall St. Rank hold FOLD as of Q1 2024.

  • Able Wealth Management reported no remaining Amicus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Able Wealth Management sold 117 Amicus Therapeutics shares in Q1 2024, an estimated $1.66K.
  • Able Wealth Management first reported a position in Amicus Therapeutics in Q4 2023 and held it in 1 quarter.
  • Able Wealth Management's Amicus Therapeutics position peaked at $1.66K in Q4 2023.
  • 254 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2024.

Based on Able Wealth Management's 13F filing for Q1 2024, filed 1 Nov 2024.